BCRX BIOCRYST PHARMACEUTICALS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Biopharmaceutical company focused on development and commercialization of pharmaceutical products, including rare disease treatments like ORLADEYO
• • Strategic shift: Sale of European ORLADEYO business with a Global Brand and Support Agreement limiting sole control over European brand positioning
• • Quantitative metric: 52-week stock price range $6.00 to $11.31 per share for fiscal year 2025
• • Noteworthy risk factor: Increased reliance on AI and cybersecurity amid expanded employee base and remote work, introducing new regulatory and operational risks

Risk Factors

• • FDA approval of ORLADEYO oral pellet for pediatric HAE patients aged 2 to <12 years in December 2025
• • Revenues from European ORLADEYO business divested in October 2025 for $254.5M cash proceeds
• • Operational dependency risk from divestiture of BioCryst Ireland holding European ORLADEYO assets and employees
• • Competitive risk from ongoing clinical development of Navenibart showing sustained HAE attack suppression in long-term trial
• • Potential revenue milestone up to $14.0M from Neopharmed Gentili contingent on European sales before December 2032

Management Discussion & Analysis

• • No revenue or YoY change figures provided in the MD&A section
• • No specific profitability or margin % data disclosed
• • No segment performance numbers or ranking included
• • Merger-related expenses expected to be substantial but no $ amounts given
• • Key risks: economic instability affecting counterparties, Merger integration challenges, clinical trial uncertainties, regulatory approval delays, and rare disease market complexities impacting future results and capital needs

What are the latest BCRX SEC filings in 2026?

BIOCRYST PHARMACEUTICALS INC (BCRX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BCRX file its most recent 10-K annual report?

BIOCRYST PHARMACEUTICALS INC (BCRX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BCRX 10-Q quarterly reports?

BIOCRYST PHARMACEUTICALS INC (BCRX)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every BCRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BCRX filed recently?

BIOCRYST PHARMACEUTICALS INC (BCRX)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BCRX insider trading activity (Form 4)?

SignalX aggregates every BCRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BCRX file with the SEC?

BIOCRYST PHARMACEUTICALS INC (BCRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BCRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for BIOCRYST PHARMACEUTICALS INC (BCRX).

What is BCRX's SEC CIK number?

BIOCRYST PHARMACEUTICALS INC (BCRX)'s SEC CIK (Central Index Key) number is 882796. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 882796 to look up all BCRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BCRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from BIOCRYST PHARMACEUTICALS INC (BCRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.